SynthesisEuropean journal of pediatrics2005
A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Synthesis in European journal of pediatrics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 140 citations in OpenAlex.
- Trial
- Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study.Pediatric cardiology · 2010Trial
- Neonatal acute kidney injury and the patent ductus arteriosus.Pediatric nephrology (Berlin, Germany) · 2026Review
- Understanding the Impact of Patent Ductus Arteriosus and Treatment Strategies on Acute Kidney Injury in Preterm Infants.American journal of perinatology · 2026Review
- α-Adrenergic blockade impairs ductus venosus shunting during an acute period of fetal hypoxaemia without further deficits to cerebral oxygen delivery.Experimental physiology · 2026Article
- Clinical Impact of the PDA and Its Management on Outcomes of Preterm Infants with NEC: A Review.American journal of perinatology · 2026Review
- Evaluation ofJournal of cardiovascular development and disease · 2026Article
- Comparison of the Effectiveness of Paracetamol and Ibuprofen in the Management of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial.Molecular and cellular pediatrics · 2025Article
- A comparison of different dosing regimen of intravenous paracetamol for hemodynamically significant patent ductus arteriosus closure in premature neonates <32 weeks: a prospective observational study.Journal of perinatology : official journal of the California Perinatal Association · 2024Observational
- Clinical Dilemma Involving Treatments for Very Low-Birth-Weight Infants and the Potential Risk of Necrotizing Enterocolitis: A Narrative Literature Review.Journal of clinical medicine · 2023Review
- Acute resveratrol exposure does not impact hemodynamics of the fetal sheep.Physiological reports · 2023Article
- Platelet Count and Volume and Pharmacological Closure with Paracetamol of Ductus Arteriosus in Preterm Infants.Children (Basel, Switzerland) · 2022Article
- Factors affecting the effectiveness of oral ibuprofen in the treatment of patent ductus arteriosus in preterm infants.International journal of clinical pharmacy · 2021Article
- Survey of PDA management in very low birth weight infants across Italy.Italian journal of pediatrics · 2020Article
- Oral ibuprofen is superior to oral paracetamol for patent ductus arteriosus in very low and extremely low birth weight infants.Medicine · 2019Observational
- Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.Seminars in perinatology · 2018Review
- The Effects of Oral Ibuprofen on Medicinal Closure of Patent Ductus Arteriosus in Full-Term Neonates in the Second Postnatal Week.Iranian journal of pediatrics · 2016Article
- Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.Early human development · 2015Article
- High-Dose Oral Ibuprofen in Treatment of Patent Ductus Arteriosus in Full-Term Neonates.Iranian journal of pediatrics · 2015Article
- Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.Paediatric drugs · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledIbuprofen (IBU) has previously been shown to be as effective as indomethacin (INDO) in closing the patent ductus arteriosus (PDA) of preterm infants, without severely affecting renal hemodynamics or basal cerebral blood flow. We conducted a meta-analysis of randomized trials to compare the efficacy and safety of IBU and INDO for treatment of PDA. Data from the nine relevant trials ( n =566), showed no significant difference in the efficacy of IBU and INDO in PDA closure ( P =0.70). However, five trials ( n =443) provided serum creatinine concentration data that revealed a significantly lower increase favoring IBU ( P < 0.001), and urine output data that showed a significantly lower decrease favoring IBU ( P < 0.001). In two trials ( n =188) the proportion of infants who required postnatal oxygen therapy at 28 days (defined as chronic lung disease) was significantly higher with IBU (52/94; 55.3%) than with INDO (38/94; 40.4%, P < 0.05). No statistically significant differences were found in mortality, intraventricular hemorrhage, necrotizing enterocolitis, surgical ligation, sepsis, retinopathy of prematurity, periventricular leukomalacia, length of hospital stay, gastrointestinal bleeding, re-opening of PDA, back-up treatment, surfactant therapy, or days on a ventilator.
conclusionibuprofen and indomethacin have similar efficacy in patent ductus arteriosus closure, but preterm infants treated with ibuprofen experience lower serum creatinine values, higher urine output, and less undesirable decreased organ blood flow and vasoconstrictive adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.